Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis by Verbelen, M. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1038/tpj.2015.5
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Verbelen, M., Collier, D. A., Cohen, D., MacCabe, J. H., & Lewis, C. M. (2015). Establishing the characteristics
of an effective pharmacogenetic test for clozapine-induced agranulocytosis. The pharmacogenomics journal,
15(5), 461-466. 10.1038/tpj.2015.5
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
OPEN
ORIGINAL ARTICLE
Establishing the characteristics of an effective pharmacogenetic
test for clozapine-induced agranulocytosis
M Verbelen1, DA Collier1,2, D Cohen3, JH MacCabe4 and CM Lewis1,5
Clozapine is the only evidence-based therapy for treatment-resistant schizophrenia, but it induces agranulocytosis, a rare but
potentially fatal haematological adverse reaction, in less than 1% of users. To improve safety, the drug is subject to mandatory
haematological monitoring throughout the course of treatment, which is burdensome for the patient and one of the main reasons
clozapine is underused. Therefore, a pharmacogenetic test is clinically useful if it identiﬁes a group of patients for whom the
agranulocytosis risk is low enough to alleviate monitoring requirements. Assuming a genotypic marker stratiﬁes patients into a
high-risk and a low-risk group, we explore the relationship between test sensitivity, group size and agranulocytosis risk. High
sensitivity minimizes the agranulocytosis risk in the low-risk group and is essential for clinical utility, in particular in combination
with a small high-risk group.
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INTRODUCTION
Although there are 22 FDA-approved antipsychotics used to treat
schizophrenia, around 30% of schizophrenia patients do not
respond to drugs other than clozapine.1 Clozapine has superior
efﬁcacy for positive symptoms in these treatment-resistant
patients2 and may improve negative symptoms.3 Furthermore,
clozapine reduces suicidal behaviour especially when compared
with ﬁrst generation antipsychotics and overall mortality at
population level.4–8
Despite its proven efﬁcacy, the clinical use of clozapine is
limited by the risk of agranulocytosis, a rare but potentially fatal
adverse drug reaction, characterized by the acute loss of neutro-
phils in circulating blood. Agranulocytosis is deﬁned as an abso-
lute neutrophil count (ANC) of less than 500 cells mm− 3 blood.
Shortly after clozapine was introduced in Europe in the 1970s, it
was withdrawn from the market when 17 cases of agranulocytosis
were reported in Finland, of which 8 were fatal.9 In 1990, clozapine
was reintroduced after its superiority over chlorpromazine for the
treatment of refractory schizophrenia was shown.10 However, its
use was restricted in most Western countries to treatment of
refractory patients, that is, patients who have not improved on at
least two different antipsychotics.2,11–13
To prevent agranulocytosis by detecting a fall in ANC, patients
treated with clozapine are subject to compulsory haematological
monitoring. In Europe, the full white blood cell count and ANC are
monitored weekly for the ﬁrst 18 weeks of treatment and every
4 weeks thereafter for the duration of the treatment.14 If at any
time during treatment the white blood cell count falls below 3000
cells mm− 3 or the ANC below 1500 cells mm− 3, clozapine should
be discontinued immediately and these patients should not be
treated with clozapine again except in a controlled setting.15–17
Although the obligatory monitoring has the beneﬁt of regular
contact with a health-care professional, it is an invasive procedure
and can be a burden for the patient. Moreover, some patients
decline to take clozapine because of the monitoring require-
ment.18
As agranulocytosis can develop within 2–5 days, even weekly
monitoring cannot guarantee timely detection in all cases.19 The
incidence of agranulocytosis induced by clozapine varies between
0.38 and 0.8%, with approximately 80% of cases occurring within
the ﬁrst 18 weeks.20–23 The incidence of agranulocytosis decreases
from 0.7% in the ﬁrst year, to 0.07% or lower in the second year of
treatment.24,25 Few cases occur later in the course of treatment,
but the risk does not fully disappear. In 2–4% of patients,
agranulocytosis is fatal, which corresponds to an overall mortality
rate of about 1–3 in 10 000 patients on clozapine.26 However,
most patients recover completely from agranulocytosis with no
haematological consequences.23,24,27
In spite of its therapeutic advantages with respect to its efﬁcacy
in treatment-resistant schizophrenia, clozapine is underused,
mainly owing to the risk of severe adverse events, primarily
agranulocytosis and the mandatory haematological monitoring.28
Around 30% of schizophrenia patients meet the indications for
clozapine treatment, but the market share of clozapine, which is
now a generic drug, was less than 5% in 2010 in the US.2
A pharmacogenetic test for clozapine-induced agranulocytosis
could greatly improve the burden of haematological monitoring if
the monitoring requirements could be made less onerous, or be
time-limited, for the majority of patients with a low genetic risk for
agranulocytosis. Not only would this make clozapine treatment
more acceptable for the patient, it would also save considerable
health-care resources. On the other hand, the patients who are at
a higher risk of developing agranulocytosis could be monitored
more frequently or, if the risk is very high, not exposed to
clozapine at all.
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Pharmacogenetic research of clozapine-induced agranulocyto-
sis has focused on candidate genes in case–control studies.
Several associations with human leukocyte antigen (HLA) alleles
have been reported, as well as associations with the tumour
necrosis factor and N-ribosyldihydronicotin-amide quinone oxido-
reductase 2 (NQO2) genes.29,30 However, few of these ﬁndings
have been replicated, and the majority of these pharmacogenetic
studies suffered from typical candidate gene study issues, namely
small sample sizes and inadequate correction for multiple testing.
The most promising ﬁnding was that the HLA-DQB1 6672G4C
polymorphism was associated with clozapine-induced agranulo-
cytosis, with an odds ratio of 16.9.31 A pharmacogenetic test
based on this polymorphism has been marketed, but owing to
low sensitivity (21.5%), it failed to be a commercial or clinical
success.29,32 In the ﬁrst genome-wide association study, amino
acid changes in HLA-DQB1 (126Q) and HLA-B (158T) were
associated with clozapine-induced agranulocytosis with more
modest odds ratios of 0.19 and 3.11, respectively.33
Here, we investigate the required properties of a clinically useful
pharmacogenetic test that could stratify clozapine users with
regards to their agranulocytosis risk as described above.
METHODS
We assume that the genetic test divides patients into two groups with
different levels of agranulocytosis risk, and that the low-risk (LR) group
contains a higher proportion of patients than the high-risk (HR) group.
When comparing the outcome of a pharmacogenetic agranulocytosis test
with the actual agranulocytosis status, the following scenarios can occur
(Table 1):
● True positive: A patient who does develop agranulocytosis is correctly
identiﬁed as HR. This scenario has probability a.
● False positive: A patient who does not develop agranulocytosis is
wrongly identiﬁed as HR. This scenario has probability b.
● False negative: A patient who does develop agranulocytosis is wrongly
identiﬁed as LR. This scenario has probability c.
● True negative: A patient who does not develop agranulocytosis is
correctly identiﬁed as LR. This scenario has probability d.
If the incidence of clozapine-induced agranulocytosis is a known
parameter k, the agranulocytosis risk regardless of test outcome (a+c)
equals k and the probability of not getting agranulocytosis (b+d) is 1-k.
Assuming that k is known, two of the following parameters need to be
ﬁxed to calculate the probabilities in each cell of Table 1:
● The proportion of patients in the HR group (x) or the proportion of
patients in the LR group (1-x).
● The sensitivity of the test, which is the proportion of correctly classiﬁed
agranulocytosis cases. In Table 1, Sensitivity ¼ aaþc ¼ ak
● The speciﬁcity of the test, which is the proportion of correctly classiﬁed
agranulocytosis-free patients. In Table 1, Specif icity ¼ dbþd ¼ d1- k
The proportion of patients in each risk group (x, 1-x) is relevant to this
study, as we want to justify a more lenient monitoring schedule for the LR
group. The larger the LR group, the more patients on clozapine will beneﬁt
from monitoring regime changes. Assuming a single locus test, the size of
the two risk groups depends on the allele frequency of the test marker.
Hence, we use the proportion of patients in the HR group (x) and test
sensitivity (s) to study the cell probabilities in Table 1.
Of primary interest is the agranulocytosis risk in the LR group, as these
are the patients for whom the haematological monitoring rules could be
relaxed, and this outcome corresponds to the complement of the negative
predictive value (NPV), being the proportion of test negative or LR patients
who do not develop agranulocytosis. Therefore, we investigate the
relationship between agranulocytosis risk in the LR group, test sensitivity
and the size of the HR group. The agranulocytosis risk in the LR group is
given by
PðA LRj Þ ¼ P A \ LRð Þ
P LRð Þ ¼
c
c þ d ¼
1 - sð Þk
1 - x
¼ 1 -NPV
where A stands for developing agranulocytosis. Thus, the agranulocytosis
risk in the LR group decreases as test sensitivity increases or as the HR
group becomes smaller, which corresponds to the LR group getting larger.
As a secondary outcome, we study the agranulocytosis risk in the HR
group, which corresponds to the positive predictive value (PPV) or the
proportion of test positive patients who are true agranulocytosis cases, and
is given by
PðA HRj Þ ¼ P A \ HRð Þ
P HRð Þ ¼
a
aþ b ¼
sk
x
¼ PPV
In the HR group, the agranulocytosis risk increases when sensitivity rises or
the proportion of patients in the HR group decreases.
By deﬁnition, the agranulocytosis risk in the HR group must be larger
than in the LR group, so
P A HRj Þ > P A LRj Þðð
or expressed in terms of sensitivity and size of the HR group
sk
x
>
1 - sð Þk
1 - x
which reduces to s4x. In other words, sensitivity must be larger than the
proportion of patients in the HR group.
We explore the relationship between different parameters, focusing on
sensitivity (s), and the proportion of patients assigned to the HR group (x),
in the context of a genetic test to predict the risk of clozapine-induced
agranulocytosis. Furthermore, we develop guidelines for a test that divides
the population into a LR and HR group, assuming the total risk of
developing clozapine-induced agranulocytosis (k) is 0.8%.11 We also assess
how the pharmacogenetic test based on the HLA-DQB1 6672G4C
polymorphism performs under this framework.31
RESULTS
The key parameters for a clinically effective test, that is, a test that
minimizes the agranulocytosis risk in the LR group, are high
sensitivity and to a lesser extent a small proportion of patients
assigned to the HR group. Figure 1 shows that to obtain a low
agranulocytosis risk in the LR group (solid lines), with a con-
comitant high risk in the HR group (dotted lines), a test should be
highly sensitive. Also, for a given sensitivity, a smaller HR group
corresponds to lower agranulocytosis risk in the LR group and a
higher agranulocytosis risk in the HR group (Figure 1 and Table 2).
The lower the sensitivity of a test is, the smaller the difference
between the agranulocytosis risks in both groups. When the
sensitivity is equal to the size of the HR group, the risk in the two
groups are the same and equal to the overall agranulocytosis risk
of 0.8%. A test with sensitivity close to the proportion of patients
in the HR group would thus be irrelevant.
Exploration of the relationship between agranulocytosis risk and
the proportion of patients in the HR group conﬁrms that a smaller
HR group gives rise to a lower agranulocytosis risk in the LR group
(Figure 2). The risk in the HR group increases steeply when the size
of that group is close to zero. For a given size of the HR group,
high sensitivity leads to a low agranulocytosis risk in the LR group
and a high risk in the HR group (Figure 2 and Table 3). As in
Table 1. Classiﬁcation table comparing test outcome with true
agranulocytosis status
Test result Agranulocytosis Total
Yes No
Positive: High risk a= sk b= x-sk a+b= x
Negative: Low risk c= (1-s) k d= 1-x-(1-s) k c+d= 1-x
Total a+c= k b+d= 1-k 1
Cell probabilities are expressed in terms of sensitivity (s) and size of the HR
group (x).
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Figure 1, the risk curves in Figure 2 meet at 0.8% agranulocytosis
risk when the proportion of patients in the HR group is equal to
the sensitivity (except for 100% sensitivity where the agranulocy-
tosis risk in the LR group is zero as all agranulocytosis cases are
detected by the test).
A simultaneous assessment of sensitivity and HR group size
shows that test sensitivity controls the reduction in agranulocy-
tosis risk seen in the LR group, with high sensitivity leading to low
agranulocytosis risk (Figure 3a). High sensitivity implies that most
agranulocytosis cases are identiﬁed by the genetic test and
classiﬁed as HR. By consequence, nearly all patients in the LR
group do not develop agranulocytosis, and hence the risk in that
Figure 1. Agranulocytosis risk in LR and HR groups by sensitivity, for
different HR group sizes between 5 and 50%. The ■ and ▲ indicate
the agranulocytosis risk in the LR and HR groups, respectively, for a
test with 80% sensitivity and 10% of patients in the HR group.
Table 2. Hypothetical tests with 80% sensitivity for different
proportions of patients in the HR group, showing agranulocytosis risks
in the LR group (1-NPV), the HR group (PPV) and speciﬁcity of the test
Size of HR group P(A9LR) (1-NPV) P(A9HR) (PPV) Speciﬁcity
0.010 0.0016 0.640 0.996
0.050 0.0017 0.128 0.956
0.100 0.0018 0.064 0.906
0.200 0.0020 0.032 0.805
0.300 0.0023 0.021 0.704
0.400 0.0027 0.016 0.603
0.500 0.0032 0.013 0.502
Abbreviations: HR, high risk; LR, low risk; NPV, negative predictive value;
PPV, positive predictive value.
Figure 2. Agranulocytosis risk in LR and HR groups by proportion of
patients that classiﬁed as HR, for different sensitivity values between
20 and 100%.
Table 3. Hypothetical tests with 10% of patients in the HR group for
different sensitivity values, showing agranulocytosis risks the LR group
(1-NPV), in the HR group (PPV) and speciﬁcity of the test
Sensitivity P(A9LR) (1-NPV) P(A9HR) (PPV) Speciﬁcity
0.200 0.0071 0.016 0.901
0.400 0.0053 0.032 0.902
0.600 0.0036 0.048 0.904
0.800 0.0018 0.064 0.906
1 0 0.080 0.907
Abbreviations: HR, high risk; LR, low risk; NPV, negative predictive value;
PPV, positive predictive value.
Figure 3. Agranulocytosis risk in (a) LR group and (b) HR group by
sensitivity and proportion of patients in the HR group. In both
panels, darker colours represent the desired outcomes of low risk in
the LR group and high risk in the HR group. The letters indicate the
position of hypothetical tests A, B, C and D; HLA indicates the
position of the HLA-DQB1 6672G4C-based test.
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group is low. For example, if we need the agranulocytosis risk in
the LR group to be half the population risk, (that is, ⩽ 0.4%), the
test sensitivity must be at least 50.2%. To achieve a stratiﬁcation
where the LR group is at one-ﬁfth of the average agranulocytosis
risk, sensitivity greater than 80.1% is required. A small HR group
contributes to a low agranulocytosis risk in the LR group by
preventing true LR patients from being wrongly classiﬁed as HR. A
large number of true LR patients maximizes the denominator of
the agranulocytosis risk in the LR group, and thus minimizes the
risk itself.
The agranulocytosis risk in the HR group depends largely on the
size of the HR group (Figure 3b). In a smaller HR group, the ratio of
true HR patients versus patients incorrectly classiﬁed as HR is
larger, and so the agranulocytosis risk in the HR group is larger.
High sensitivity increases the number of true HR patients and in
that way leads to a high agranulocytosis risk in this group, but
even in the ideal scenario of maximum sensitivity, the proportion
of true HR patients is limited to 0.8%.
High sensitivity and a small HR group lead to an effective test
with the small group of HR patients requiring more frequent
monitoring, whereas the majority of patients are assigned to the
LR group, which has substantially reduced agranulocytosis risk
and could therefore be monitored less frequently.
To comment on the clinical utility of a pharmacogenetic test, an
agranulocytosis risk that is acceptable without monitoring must
be determined. We propose that an agranulocytosis risk of 0.13%
is acceptable, because this corresponds to the risk conferred by
the antipsychotic chlorpromazine which does not have mandatory
monitoring in the UK.34,35 To achieve this, the sensitivity of the test
must be at least 83.9%. We examine four hypothetical pharma-
cogenetic tests and how the outcomes affect haematological
monitoring of patients (Table 4).
● Test A is only clinically relevant for the small proportion of HR
patients, but owing to its low sensitivity, the agranulocytosis
risk in the LR group is too high to reduce monitoring.
● Despite a higher sensitivity than test A, test B has no deﬁnite
impact on the treatment of either risk group.
● The characteristics of test C result in an agranulocytosis risk in
the LR group that is low enough to stop or reduce haema-
tological monitoring for 90% of patients. This test has the
largest clinical impact.
● Although the sensitivity of test D is higher than that of test C,
the larger size of the HR group in test D implies that fewer
patients would beneﬁt from this test.
The pharmacogenetic agranulocytosis test using the HLA-DQB1
6672G4C polymorphism has a sensitivity of 21.5% and speciﬁcity
of 98.4%.31 On the basis of those values and assuming an overall
agranulocytosis risk of 0.8%, the test classiﬁes 1.76% of patients as
HR, with a high agranulocytosis risk of 9.66%. Conversely, the
agranulocytosis risk in the LR group is 0.64%. This is a relative risk
of 0.8 or a 20% reduction in risk compared with the agranulocy-
tosis risk without genetic stratiﬁcation, and exceeds our maximum
acceptable agranulocytosis risk of 0.13%. Hence, the HLA-DQB1
6672G4C-based genetic test has limited use in stratifying patients
in order to reduce haematological monitoring requirements for a
subset of patients.
DISCUSSION
We have established a framework for assessing the utility of a
genetic test for clozapine-induced agranulocytosis and explored
the characteristics of tests that would reduce agranulocytosis risk
to a level that does not require regular haematological monitor-
ing. In particular, we show that high sensitivity is essential and that
a small proportion of patients classiﬁed as HR further decreases
the agranulocytosis risk in the LR group.
High sensitivity is a self-evident characteristic of a clinically
useful test, but the ﬁnding that a small HR group is favourable
might seem counterintuitive. One could reason that to be sure the
LR group contains no agranulocytosis cases, the HR group should
include all patients who are at the slightest risk of developing
agranulocytosis, and that the HR group should thus be large.
However, as the number of true agranulocytosis cases is very low,
a large HR group would mainly contain false-positive patients.
Instead of a large HR group, a useful test relies on high sensitivity
to correctly classify the agranulocytosis cases as HR. A small HR
group implies few false positives and many true negatives, which
in turn minimizes the agranulocytosis risk in the LR group.
Instead of a single genetic locus, a pharmacogenetic test could
also be based on polygenic risk scores, built from combining risk
conferred by many genetic loci to identify patients at high risk. In
that case, the threshold deﬁning LR and HR groups can be varied,
and the effectiveness of a test is typically measured by the area
under a receiver operating characteristic curve.36 When the
threshold is moved to increase test sensitivity, the size of the HR
group will increase as well. It is not straightforward to predict the
resulting change—increase or decrease—in agranulocytosis risks
in the LR and HR groups, because these depend on the
distribution of the polygenic risk scores. Once an appropriate
polygenic score threshold has been ﬁxed, a test can be translated
easily to the framework developed here.
Pharmacogenetic tests for abacavir, carbamazepine and purine
analogues in clinical use have sensitivity, speciﬁcity and NPV close
to 100% (Table 5).37–39 However, the PPVs of these tests vary
between 7.7 and 80.6%. These low PPVs are acceptable, as there
are alternative treatments available for patients who test positive.
In contrast, clozapine is reserved for treatment of refractory
schizophrenia and no alternative drug is available. A high PPV
would ensure that few patients are unnecessarily excluded from
treatment, but a high NPV and consequently low agranulocytosis
risk is also important to justify a reduced monitoring schedule for
patients in the LR group.
No genetic test for clozapine-induced agranulocytosis currently
exists. The proposed test of HLA-DQB1 6672G4C has high
speciﬁcity, but low sensitivity fails to reduce the agranulocytosis
risk in the LR group sufﬁciently that monitoring could be reduced
or ceased. Candidate gene studies have failed to identify a strong,
replicated genetic variant that substantially increases risk of
Table 4. Four hypothetical pharmacogenetic tests for clozapine-induced agranulocytosis and their clinical impact
Test Sensitivity Size of HR group P(A9LR) (1-NPV) P(A9HR) (PPV) Speciﬁcity Clinical impact
A 0.500 0.004 0.004 1 1 No change in monitoring, but withhold clozapine from HR group
B 0.600 0.200 0.004 0.024 0.803 No change in monitoring
C 0.850 0.100 0.0013 0.068 0.906 Stop monitoring in LR group
D 0.950 0.500 0.0008 0.015 0.504 Stop monitoring in LR group
Abbreviations: HR, high risk; LR, low risk; NPV, negative predictive value; PPV, positive predictive value.
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clozapine-induced agranulocytosis.29,30 The ﬁrst genome-wide
association study of clozapine-induced agranulocytosis detected
signiﬁcant associations at two HLA amino acids;33 at least one
further study is in progress,40 and combined analysis of such
studies may identify associated genetic variants that can be
rapidly translated to clinical practice.
CONFLICT OF INTEREST
David A Collier is a full time employee of Eli Lilly and Company Ltd, and a visiting
Professor at King’s College London. David A Collier also holds stock in Eli Lilly and
Company. Moira Verbelen is funded by a studentship from the Medical Research
Council and Eli Lilly and Company Ltd. The remaining authors declare no conﬂict of
interest.
ACKNOWLEDGMENTS
This study was funded by an industrial CASE studentship to Moira Verbelen from the
Medical Research Council with Eli Lilly and Company Ltd, by the European
Community's Seventh Framework Programme (FP7/2007-2013) under grant agree-
ment n° 279227 (CRESTAR project, http://www.crestar-project.eu/), and under the
Marie Curie Industry-Academia Partnership and Pathways, grant agreement n°
286213 (PsychDPC, http://www.psych-dpc.eu/). This study was part-funded by the
National Institute for Health Research (NIHR) Biomedical Research Centre at South
London and Maudsley NHS Foundation Trust and King’s College London. The views
expressed are those of the authors and not necessarily those of the NHS, the NIHR or
the Department of Health.
REFERENCES
1 Meltzer HY. Treatment-resistant schizophrenia - the role of clozapine. Curr Med
Res Opin 1997; 14: 1–20.
2 Meltzer HY. Clozapine: balancing safety with superior antipsychotic efﬁcacy. Clin
Schizophr Relat Psychoses 2012; 6: 134–144.
3 Joober R, Boksa P. Clozapine: a distinct, poorly understood and under-used
molecule. J Psychiatry Neurosci 2010; 35: 147.
4 Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al. Clozapine
treatment for suicidality in schizophrenia: international suicide prevention trial
(InterSePT). Arch Gen Psychiatry 2003; 60: 82–91.
5 Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, Hakkinen U, Isohanni M, Hakko H.
Antipsychotics and mortality in ﬁrst-onset schizophrenia: prospective Finnish
register study with 5-year follow-up. Schizophr Res 2013; 150: 274–280.
6 Ringback Weitoft G, Berglund M, Lindstrom EA, Nilsson M, Salmi P, Rosen M.
Mortality, attempted suicide, re-hospitalisation and prescription reﬁll for clozapine
and other antipsychotics in Sweden - a register-based study. Pharmacoepidemiol
Drug Saf 2014; 23: 290–298.
7 Reutfors J, Bahmanyar S, Jonsson EG, Brandt L, Boden R, Ekbom A et al. Medi-
cation and suicide risk in schizophrenia: a nested case-control study. Schizophr Res
2013; 150: 416–420.
8 Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A et al.
11-year follow-up of mortality in patients with schizophrenia: a population-based
cohort study (FIN11 study). Lancet 2009; 374: 620–627.
9 Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during
treatment with chlozapine. Eur J Clin Pharmacol 1977; 11: 193–198.
10 Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant
schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psy-
chiatry 1988; 45: 789.
11 Medicines and Healthcare Products Regulatory Agency Summary of Product
Characteristics: Clozaril 100mg Tablets 2014, London. http://www.mhra.gov.uk/
home/groups/spcpil/documents/spcpil/con1405056917253.pdf.
12 U.S. Food and Drug Administration Clozaril Prescribing Information 2013, U.S. Food
and Drug Administration: Silver Spring. http://www.accessdata.fda.gov/drugsatf-
da_docs/label/2013/019758s069s071lbl.pdf.
13 Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and
prescribing trends. BMC Psychiatry 2014; 14: 102.
14 European Agency for the Evaluation of Medicinal Products, Committed for Pro-
prietary Medicinal Properties ( CPMP). Summary information on referral opinion
following arbitration pursuant to Article 30 of Council Directive 2001/83/EC for
Leponex and associated names (international non-proprietary name (INN):
clozapine): Background information and Annex III. London, 2002. Retrieved from
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/
Leponex_30/WC500010966.pdf.
15 Bogers JP, Cohen D, Schulte PF, van Dijk D, Bakker B. Clozapine-induced leuko-
penia: arguments for rechallenge. Ir J Med Sci 2012; 181: 155–156.
16 Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the
possibilities and practicalities. CNS Drugs 2007; 21: 25–35.
17 Manu P, Sarpal D, Muir O, Kane JM, Correll CU. When can patients with potentially
life-threatening adverse effects be rechallenged with clozapine? A systematic
review of the published literature. Schizophr Res 2012; 134: 180–186.
18 Swinton M, Ahmed A. Reasons for non-prescription of clozapine in treatment-
resistant schizophrenia. Criminal Behaviour and Mental Health 1999; 9: 207–214.
19 Gerson SL, Meltzer H. Mechanisms of clozapine-induced agranulocytosis. Drug Saf
1992; 7 (Suppl 1): 17–25.
20 Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related
morbidity and mortality: 5 years of experience with the Clozaril National Registry.
J Clin Psychiatry 1997; 59: 3–7.
21 Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-
induced agranulocytosis-incidence and risk factors in the United States. N Engl J
Med 1993; 329: 162–167.
22 Lahdelma L, Appelberg B. Clozapine-induced agranulocytosis in Finland, 1982-
2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 2012;
73: 837–842.
23 Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active mon-
itoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharma-
covigilance. Br J Psychiatry 1999; 175: 576–580.
24 Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D. Neutropenia and
agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psy-
chiatry 1996; 169: 483–488.
25 Kumar V. Clozaril Monitoring Systems, Registry Data and Analyses (United States,
United Kingdom, and Australia). Presentation, Novartis 2002. Accessed online on
15 September 2014 http://www.fda.gov/ohrms/dockets/ac/03/slides/3959S1_02_
C-Novartis-Kumar.ppt.
Table 5. Characteristics of pharmacogenetic tests that predict adverse drug reactions
Drug Gene Test Performance characteristics Reference
Abacavir HLA-B*5701 The HLA-B*5701 allele is associated with
hypersensitivity reaction. Carriers should avoid abacavir.
Sensitivity: 100%
Speciﬁcity: 96.9%
PPV: 47.9%
NPV: 100%
37
Carbamazepine HLA-B*1502 The HLA-B*1502 allele is associated with SJS-TEN
in Han Chinese. Carriers should avoid carbamazepine.
Sensitivity: 98.3%
Speciﬁcity: 97%
PPV: 7.7%
NPV: 100%
38
Purine analogues TPMT Impute 2 SNPs to identify patients with zero wildtype
alleles, as they are at high risk of myelotoxicity.
Sensitivity: 100%
Speciﬁcity: 99.0%
PPV: 80.6%
NPV: 100%
39
Abbreviations: HLA, human leukocyte antigen; NPV, negative predictive value; PPV, positive predictive value; SNP, single nucleotide polymorphism.
Pharmacogenetic test for clozapine-induced agranulocytosis
M Verbelen et al
5
© 2015 Macmillan Publishers Limited The Pharmacogenomics Journal (2015), 1 – 6
26 Cohen D, Bogers JP, van Dijk D, Bakker B, Schulte PF. Beyond white blood cell
monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry
2012; 73: 1307–1312.
27 Mendelowitz AJ, Gerson SL, Alvir JMJ, Lieberman JA. Clozapine-induced agranu-
locytosis. CNS Drugs 1995; 4: 412–421.
28 Nair B, MacCabe JH. Making clozapine safer: current perspectives on improving its
tolerability. Future Neurology 2014; 9: 313–322.
29 Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side
effects and agranulocytosis. Curr Psychiatry Rep 2011; 13: 156–165.
30 Opgen-Rhein C, Dettling M. Clozapine-induced agranulocytosis and its genetic
determinants. Pharmacogenomics 2008; 9: 1101–1111.
31 Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA,
Pierz KA et al. Candidate gene analysis identiﬁes a polymorphism in HLA-DQB1
associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011; 72:
458–463.
32 Spencer BW, Prainsack B, Rujescu D, Giegling I, Collier DA, Gaughran F et al.
Opening Pandora's box in the UK: a hypothetical pharmacogenetic test for
clozapine. Pharmacogenomics 2013; 14: 1907–1914.
33 Goldstein JI, Fredrik Jarskog L, Hilliard C, Alﬁrevic A, Duncan L, Fourches D et al.
Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B
alleles. Nat Commun 2014; 5: 4757.
34 Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum
Psychopharmacol 2008; 23 (Suppl 1): 27–41.
35 Medicines and Healthcare Products Regulatory Agency Summary of Product Char-
acteristics: Largactil 25mg/ml Solution for Injection 2014, London. Retrieved from http://
www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1391143096918.pdf.
36 Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for eval-
uating diagnostic tests and predictive models. Circulation 2007; 115: 654–657.
37 Mallal S, Phillips E, Carosi G, Molina J-M, Workman C, Tomažič J et al. HLA-B* 5701
screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568–579.
38 Ferrell PB, McLeod HL. Carbamazepine, HLA-B* 1502 and risk of Stevens-Johnson
syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharma-
cogenomics 2008; 9: 1543–1546.
39 Almoguera B, Vazquez L, Connolly JJ, Bradﬁeld J, Sleiman P, Keating B et al.
Imputation of TPMT defective alleles for the identiﬁcation of patients with high-
risk phenotypes. Front Genet 2014; 5: 96.
40 CRESTAR. CRESTAR – development of pharmacogenomic biomarkers for schizo-
phrenia. 2011. Accessed online on 21 May 2014 http://www.crestar-project.eu/.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
Pharmacogenetic test for clozapine-induced agranulocytosis
M Verbelen et al
6
The Pharmacogenomics Journal (2015), 1 – 6 © 2015 Macmillan Publishers Limited
